Californian biotech General Proximity announced its emergence from stealth on Friday, unveiling its proprietary OmniTAC ...

China’s National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of Dovbleron ...

Santhera partners with Clinigen to supply Agamree for Duchenne muscular dystrophy in regions without commercial availability.

WuXi Biologics has signed a deal with Sino Biopharm to develop a first-in-class monoclonal antibody targeting an undisclosed ...

Regeneron acquires UK-based Oxular, adding ocular delivery technology and Phase II therapy OXU-001 for diabetic macular edema ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

Kazia Therapeutics faces a setback as the FDA deems accelerated approval for brain cancer drug paxalisib unlikely despite ...

One of the most promising areas of medical innovation in the next five years is immuno-oncology (I-O)/cancer therapeutics ...

California-based IDEAYA Biosciences has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo ...

Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that ...

It has been a year since the launch of Zepbound (tirzepatide) for obesity, and US pharma major Eli Lilly’s competition with ...

Hutchmed sells its 45% stake in SHPL for $608 million, aligning with its focus on oncology and immunology. Proceeds will fund ...